Key Drivers
- Margin strength
- Strong liquidity
- Elevated leverage
AIAI Summary
HAE now looks like a self-funding growth-and-repair story rather than a pure defensive med-tech name, with earnings beats, stronger plasma momentum, and solid free cash flow improving the case—but after the re-rating, investors need continued execution on margins and deleveraging to justify further upside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin strength
- •Strong liquidity
- •Elevated leverage
HAE shows healthy margins, strong cash generation, and solid liquidity, but elevated leverage and premium valuation limit upside.
Price Behavior
Key Price Behavior Insights:
- •Uptrend intact
- •Breakout support
- •Short-term extended
HAE has rallied steadily over the last month, breaking above the $87.00–$88.00 zone and nearing $91.34 resistance, but the fast move leaves it short-term extended and vulnerable to a pause.
Sharp rise from the high-$70s to $90.80 over the last month suggests near-term volatility risk
Sentiment & News
Key News Insights:
- •Earnings Beat
- •Raised Guidance
- •International Exposure
Haemonetics delivered a strong Q1 fiscal 2027 beat, raised full-year guidance on Plasma growth and cash generation, and added operational and board momentum despite some caution around international sales.
The update is likely supportive for HAE shares near term, as better-than-expected results and higher guidance outweigh lingering regional sales and ownership concerns
Similar Companies in Healthcare
Other companies in the same sector with AI ratings